News

AstraZeneca shares outperform market slump after upbeat Jefferies comments
Analysts argue drugmaker is ‘at a turning point’
-
AstraZeneca shares sold off as pharmco posts drop in FY revenues February 2018
Group flags rise in product sales this year
-
AstraZeneca remains ‘top pick’ for Barclays December 2017
Analysts upbeat on the Anglo-Swedish drugmaker’s pipeline
-
Deutsche Bank remains bullish on AstraZeneca December 2017
Analysts point to encouraging drug trial results
-
AstraZeneca warns of $35m hit from higher duty
Financial hit related to Brexit
December 2017 -
AstraZeneca shares in demand after asthma drug approval
FDA endorses benralizumab
November 2017 -
AstraZeneca lifts earnings guidance
Company reports receding impact from loss of exclusivity
November 2017 -
FDA grants priority review status to AstraZeneca’s Imfinzi
Credit Suisse praises pharmco’s recent progress
October 2017 -
Exane BNP Paribas turns bullish on AstraZeneca
Analysts point to ‘concentration of value’ in pipeline
September 2017 - More news
-
AstraZeneca share price in focus as Amgen ends psoriasis drug partnership
Amgen is ending its partnership with AstraZeneca to develop a psoriasis treatment after observing suicidal thoughts in patients in a trial.
May 2015 -
AstraZeneca share price: Pharmco to invest $285m in biotech facility
AstraZeneca is investing $285 million in a biotech facility in Sweden.
May 2015 -
AstraZeneca share price: Pharmco dives deeper into personalised healthcare
AstraZeneca inks two research deals which will see it explore the potential of personalised healthcare in heart and respiratory diseases.
May 2015 -
drug maker receives EU approval for child flu vaccine
UK pharmaceutical giant mulls Forest Laboratories bid, sources say
December 2013 -
Analysts see drugmaker as viable takeover target
Improved Pfizer bid to negate US anti-inversion measures, Jefferies analysts say
October 2014 - More news